

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7756274

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	RIDGELINE THERAPEUTICS GMBH	06/02/2022
RECEIVING PARTY DATA		
Name:	BRIGHT PEAK THERAPEUTICS AG	
Street Address:	KLYBECKSTRASSE 191	
City:	BASEL	
State/Country:	SWITZERLAND	
Postal Code:	4057	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17144537
CORRESPONDENCE DATA		
Fax Number:	(858)252-6503	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	858-252-6502	
Email:	PatentDocket@eversheds-sutherland.com, shaejackson@eversheds-sutherland.com	
Correspondent Name:	EVERSHEDS SUTHERLAND (US) LLP	
Address Line 1:	12255 EL CAMINO REAL	
Address Line 2:	SUITE 100	
Address Line 4:	SAN DIEGO, CALIFORNIA 92130	
ATTORNEY DOCKET NUMBER:	94917-0003.702201US	
NAME OF SUBMITTER:	SHAE JACKSON	
SIGNATURE:	/Shae Jackson/	
DATE SIGNED:	01/23/2023	
Total Attachments: 2		
source=94917-0003.702201US-RT to BP Executed Assignment#page1.tif		
source=94917-0003.702201US-RT to BP Executed Assignment#page2.tif		

CORPORATE TO CORPORATE PATENT ASSIGNMENTDocket Number 94917-0003.702201US |
94917-0004.702601WO

WHEREAS, Ridgeline Therapeutics GmbH, a Corporation incorporated under the laws of Switzerland, having a place of business at Aeschenvorstadt 36, CH 4051 Basel, Switzerland, (hereinafter "Assignor"), owns its entire right, title, and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF

- ☒ for which application serial number 17/144,537 was filed on January 8, 2021 in the United States Patent and Trademark Office;
- ☒ for which a PCT Application Serial No. PCT/IB2021/000004 was filed on January 8, 2021 with the US Receiving Office for the Patent Cooperation Treaty;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Bright Peak Therapeutics AG, a corporation in the country of Switzerland, having a place of business at Klybeckstrasse 191, Basel, Switzerland 4057, (hereinafter "Assignee"), is desirous of acquiring its entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protections thereon granted in the United States, foreign countries or under any international convention, agreement, and protocol, or treaty, including those filed under the Paris Conventions for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest: (a) in and to said inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuations, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).



2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance, all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting, substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissue of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said inventions, and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby requests that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

<p align="center">CORPORATE TO CORPORATE PATENT ASSIGNMENT</p>	<p>Docket Number 94917-0003.702201US 94917-0004.702601WO</p>
<p align="center">IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the dates written below:</p>	
<p>RECEIVED AND AGREED TO BY ASSIGNOR: <u>Ridgeline Therapeutics GmbH</u> Date: <u>02/06/2022</u> Signature: <u></u> Name: <u>ANDREW J. H. CHEN</u> Title: <u>COO</u></p>	
<p>RECEIVED AND AGREED TO BY ASSIGNEE: <u>Bright Peak Therapeutics AG</u> Date: <u>June 3, 2022</u> Signature: <u></u> Name: <u>Matthew Robbins</u> Title: <u>General Counsel</u></p>	